Tocagen awarded grant by Voices Against Brain Cancer

Thursday, June 20, 2013 12:52 PM

Voices Against Brain Cancer (VABC), a nonprofit organization dedicated to finding a cure for brain cancer, has awarded Tocagen, a privately held biopharmaceutical, a grant to support the clinical investigation of Toca 511 & Toca FC in patients diagnosed with a recurrent high grade glioma brain cancer (Grade 3 or Grade 4). 

"Toca 511 & Toca FC is a promising new approach in clinical trials that has the potential to help patients with brain cancer, and we are excited to provide support for this program," said Mario Lichtenstein, co-founder of VABC. 

Tocagen is enrolling patients in phase I clinical trials at sites across the U.S.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs